BG61366B2 - Използване на съединения на метокси алифатните киселини с индазол за получаване на фармацевтично средство за лечение на автоимунни заболявания - Google Patents

Използване на съединения на метокси алифатните киселини с индазол за получаване на фармацевтично средство за лечение на автоимунни заболявания Download PDF

Info

Publication number
BG61366B2
BG61366B2 BG98590A BG9859094A BG61366B2 BG 61366 B2 BG61366 B2 BG 61366B2 BG 98590 A BG98590 A BG 98590A BG 9859094 A BG9859094 A BG 9859094A BG 61366 B2 BG61366 B2 BG 61366B2
Authority
BG
Bulgaria
Prior art keywords
compound
formula
autoimmune
preparation
treatment
Prior art date
Application number
BG98590A
Other languages
Bulgarian (bg)
English (en)
Inventor
Bruno Silvestrini
Original Assignee
Angelini Ricerche S.P.A. Societa'consortile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angelini Ricerche S.P.A. Societa'consortile filed Critical Angelini Ricerche S.P.A. Societa'consortile
Publication of BG61366B2 publication Critical patent/BG61366B2/bg

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BG98590A 1991-04-22 1994-02-25 Използване на съединения на метокси алифатните киселини с индазол за получаване на фармацевтично средство за лечение на автоимунни заболявания BG61366B2 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI911101A IT1253703B (it) 1991-04-22 1991-04-22 Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie

Publications (1)

Publication Number Publication Date
BG61366B2 true BG61366B2 (bg) 1997-06-30

Family

ID=11359721

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98590A BG61366B2 (bg) 1991-04-22 1994-02-25 Използване на съединения на метокси алифатните киселини с индазол за получаване на фармацевтично средство за лечение на автоимунни заболявания

Country Status (16)

Country Link
US (1) US5278183A (de)
EP (1) EP0510748B1 (de)
JP (1) JP3056879B2 (de)
KR (1) KR100210199B1 (de)
AT (1) ATE135573T1 (de)
AU (1) AU657524B2 (de)
BG (1) BG61366B2 (de)
CA (1) CA2066304C (de)
CZ (1) CZ280613B6 (de)
DE (1) DE69209128T2 (de)
DK (1) DK0510748T3 (de)
IL (1) IL101660A (de)
IT (1) IT1253703B (de)
NZ (1) NZ242392A (de)
SK (1) SK278546B6 (de)
ZA (1) ZA922740B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723315B1 (fr) * 1994-08-02 1996-10-25 Cird Galderma Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
JP2005510492A (ja) * 2001-10-26 2005-04-21 ユニバーシティ オブ コネチカット 新規な種類の効力のあるカンナビミメティックリガンド
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
AU2009221087B2 (en) 2008-03-07 2013-12-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
DK2262777T3 (en) 2008-03-07 2016-05-17 Acraf 1-benzyl-3-hydroxymetylindazolderivater and their use in the treatment of diseases based on the expression of MCP-1 and CX3CR1
JP5509101B2 (ja) * 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な1−ベンジル−3−ヒドロキシメチルインダゾール誘導体、ならびにそのMCP−1、CX3CR1およびp40の発現に基づく疾患の治療への使用
MX2012001520A (es) 2009-08-03 2012-06-01 Acraf Proceso para la preparacion de 1-bencil-3-hidroximetil-1h-indazol y sus derivados e intermediarios de magnesio requeridos.
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1194564B (it) * 1983-04-18 1988-09-22 Acraf Impiego del bendazac e dei suoi sali nel trattamento della retinite pigmentosa
EP0191520B1 (de) * 1985-02-12 1989-06-21 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (1-Phenylmethyl-5-hydroxy-1H-indazol-3-yl)-oxyessigsäure und deren Salze zur Verwendung als Heilmittel und diese enthaltende pharmazeutische Zusammensetzungen
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo

Also Published As

Publication number Publication date
AU1488392A (en) 1992-10-29
KR100210199B1 (ko) 1999-07-15
DE69209128D1 (de) 1996-04-25
ZA922740B (en) 1992-12-30
SK278546B6 (en) 1997-09-10
JPH0640915A (ja) 1994-02-15
AU657524B2 (en) 1995-03-16
CZ280613B6 (cs) 1996-03-13
ATE135573T1 (de) 1996-04-15
EP0510748A1 (de) 1992-10-28
DE69209128T2 (de) 1996-11-28
KR920019350A (ko) 1992-11-19
NZ242392A (en) 1997-06-24
ITMI911101A0 (it) 1991-04-22
CA2066304A1 (en) 1992-10-23
CA2066304C (en) 2005-06-21
DK0510748T3 (da) 1996-07-22
US5278183A (en) 1994-01-11
IT1253703B (it) 1995-08-23
EP0510748B1 (de) 1996-03-20
JP3056879B2 (ja) 2000-06-26
ITMI911101A1 (it) 1992-10-22
IL101660A (en) 1996-08-04
CS122792A3 (en) 1992-11-18

Similar Documents

Publication Publication Date Title
KR100464693B1 (ko) 5-메틸이소옥사졸-4-카복실산-(4-트리플루오로메틸)-아닐리드와n-(4-트리플루오로메틸페닐)-2-시아노-3-하이드록시크로톤산아미드와의배합물을함유하는제제
BG61366B2 (bg) Използване на съединения на метокси алифатните киселини с индазол за получаване на фармацевтично средство за лечение на автоимунни заболявания
KR20140035538A (ko) 선별적 s1p₁ 수용체 작동약에 대한 투약 섭생
US20060173011A1 (en) Treatment of inflammatory disorders with praziquantel
KR20080098494A (ko) 염증 질환 치료를 위한 gabaa-활성화된 신경전달을 증진시키는 화합물의 용도
KR20010015890A (ko) 신경변성질환 치료약
BRPI0615046A2 (pt) uso de um composto, e, formulação para administração oral
US20050215601A1 (en) Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
CN1477957A (zh) 用于治疗高血氨症及肝性脑病的含二氢呋喃环结构的丹参酮类化合物
US20050070565A1 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
JPS6056920A (ja) 脂質レベルの低減方法
Wurtman et al. Dietary enhancement of CNS neurotransmitters
Pfeiffer et al. ON THE MECHANISM OF THE NULLIFICATION OF CNS EFFECTS OF l‐DOPA BY PYRIDOXINE IN PARKINSONIAN PATIENTS 1
RU2160102C2 (ru) Применение бензидамина для лечения патологических состояний, вызванных фно
US4880803A (en) Method of inducing immunostimulating activity
US4478845A (en) Antiinflammatory and/or analgesic imidazoimidazoles
US3906107A (en) Aminoalkyl sulfate esters with diuretic activity
Austin et al. Rate of formation of norpethidine from pethidine
EA000166B1 (ru) Биологически активные уреидо-производные, полезные при лечении рассеянного склероза
HU219406B (hu) Eljárás autoimmun betegségek kezelésére alkalmas, benzil-indazol-származékokat tartalmazó gyógyszerkészítmények előállítására
Beck et al. Cortical EEG stimulant effects in the rabbit of acetaldehyde-biogenic amine reaction products
JPS62198616A (ja) 脳血流量改善・脳細胞保護剤
DE69919995T2 (de) Verwendung von cysteinprotease inhibitoren zur herstellung eines arzneimittels zur vorgbeugung und behandlung von gehirngewebezerrütung infolge hypertensive enzephalopathie oder encephalothlipsis
Mizutani et al. Studies on Absorption and Excretion of Drugs. XXIX. Biopharmaceutical Studies on Guaiacol Glycerol Ether and Related Compounds. I. Blood Level of Guaiacol Glycerol Ether in Rabbit and Its Binding with Serum Proteins.
JPS6345371B2 (de)